The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity by Gonzalez-Alvaro, I. et al.
RESEARCHARTICLE
The comparative responsiveness of Hospital
Universitario Princesa Index and other
composite indices for assessing rheumatoid
arthritis activity
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To evaluate the responsiveness in terms of correlation of the Hospital Universitario La Prin-
cesa Index (HUPI) comparatively to the traditional composite indices used to assess dis-
ease activity in rheumatoid arthritis (RA), and to compare the performance of HUPI-based
response criteria with that of the EULAR response criteria.
Methods
Secondary data analysis from the following studies: ACT-RAY (clinical trial), PROAR
(early RA cohort) and EMECAR (pre-biologic era long term RA cohort). Responsiveness
was evaluated by: 1) comparing change from baseline (Δ) of HUPI with Δ in other scores
by calculating correlation coefficients; 2) calculating standardised effect sizes. The accu-
racy of response by HUPI and by EULAR criteria was analyzed using linear regressions
in which the dependent variable was change in global assessment by physician (ΔGDA-
Phy).
Results
ΔHUPI correlation with change in all other indices ranged from 0.387 to 0.791); HUPI’s stan-
dardized effect size was larger than those from the other indices in each database used. In
ACT-RAY, depending on visit, between 65 and 80% of patients were equally classified by
HUPI and EULAR response criteria. However, HUPI criteria were slightly more stringent,
with higher percentage of patients classified as non-responder, especially at early visits.
HUPI response criteria showed a slightly higher accuracy than EULAR response criteria
when using ΔGDA-Phy as gold standard.
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Conclusion
HUPI shows good responsiveness in terms of correlation in each studied scenario (clinical
trial, early RA cohort, and established RA cohort). Response criteria by HUPI seemmore
stringent than EULAR’s.
Introduction
Objective evaluation of disease activity in rheumatoid arthritis (RA) has become a keystone of
disease management. Composite indices measuring disease activity have allowed implement-
ing treat-to-target and tight-control strategies, both contributing the most to the improvement
in RA outcome achieved in the last 15 years. The most frequently used indices to evaluate dis-
ease activity among rheumatologists are the Disease Activity Score (DAS28) [calculated with
C-reactive protein (CRP) or with sedimentation rate (ESR)] and the Simplified Disease Activ-
ity Index (SDAI), since they have been widely validated, are endorsed by ACR and EULAR,
and are commonly used to assess therapeutic response in clinical trials [1–5]. In addition, the
Clinical Disease Activity Index (CDAI) is being increasingly used, as it is easier to calculate
than the previous ones, despite limited validation.
However, during the last 10 years, a fair amount of evidence suggested that both, DAS28
and SDAI, present a gender bias, derived from differences between men and women in terms
of pain perception and levels of erythrocyte sedimentation rate (ESR)[6–10]. Using these indi-
ces, the implementation of T2T strategy would be biased, leading to over-treatment in women,
or under-treatment of men. This may lead to excess risk of adverse events in women or lower
odds to achieve real disease control in men. In addition, assessment of response to treatment
in clinical trials might also be biased [11].
The Hospital Universitario La Princesa Index (HUPI) was developed to avoid a gender bias
in the assessment of RA disease activity by adjusting the contribution of tender joint counts
and ESR by sex [12]. An additional advantage of HUPI is that it can be calculated with ESR,
CRP, or both acute phase reactants (APR), producing an almost identical score and avoiding
missing data in longitudinal studies [12, 13].
HUPI was initially developed and validated in PEARL, a longitudinal observational study
nested in an early arthritis register, and is calculated as the sum of four variables (graded 0–3
according to their quartile distribution in the PEARL population [see S1 Table]): 28 tender
and swollen joint counts, global disease assessment by patient and APR [13]. When both ESR
and CRP are used to calculate the index, the average of their scores in S1 Table is used to calcu-
late HUPI. Thus, the index ranges from 0 to 12, and its cut-offs for remission/low disease activ-
ity, low/moderate and moderate/high disease activity are 2, 5 and 9 respectively [13]. HUPI
may have a “ceiling effect”, especially in groups of patients with very high disease activity, such
as those included in clinical trials.
The objective of this study was to evaluate the responsiveness of the HUPI, in parallel to
that of the classical indices—DAS28-ESR, DAS28-CRP, SDAI and CDAI—, in terms of corre-
lation, using data from three cohorts. Furthermore, the performance of HUPI-based response
criteria was compared with that of EULAR response criteria.
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Patients andmethods
Patients
As mentioned, HUPI was developed in PEARL, an early arthritis register from Madrid (Spain)
[12]. In the present study, we evaluate it in other RA populations, including RA from other
countries. HUPI was evaluated in three different scenarios: a) an international clinical trial, the
ACT-RAY—very high disease activity at baseline, homogeneous intervention, strict follow-up
and patients enrolled in different countries; b) an early arthritis population (PROAR) in which
sensitivity to change may be tested in a setting different from the early arthritis population
used to develop and validate HUPI; and c) a long term prevalent RA population engaged in
the pre-biologic era (EMECAR).
The ACT-RAY clinical trial. ACT-RAY is a 2-year double-blind clinical trial
(NCT00810199, EudraCT No 2008-001847-20) designed to evaluate the efficacy and safety of
tocilizumab plus methotrexate or tocilizumab plus placebo in patients with persistent active
disease despite methotrexate monotherapy. Inclusion criteria for ACT-RAY were RA classifi-
cation according to 1987 ACR criteria [14], DAS28>4.4, and erosive disease, as described pre-
viously [15]. Data collected included demographics, RA characteristics, as well as baseline and
4-weekly clinical and laboratory data necessary to calculate DAS28-ESR, DAS28-CRP, SDAI,
CDAI and HUPI [15, 16].
Since no relevant differences in clinical response were reported between patients treated
with tocilizumab in monotherapy or in combination with methotrexate [15], we included
patients’ data irrespective of their allocation group. Considering that after the first year,
patients in ACT-RAY were allocated into four different T2T strategies [16], for the present
study the analysis was performed only with data from baseline and 12, 24 and 52 weeks visits.
The PROAR cohort. PROAR was a longitudinal multicenter study including 5 consecu-
tive patients from 34 Rheumatology Units in Spain. Patients were included if presented at least
one swollen joint for less than a year, irrespective of fulfilling 1987 ACR criteria [14]. At base-
line, patients should be naïve for disease modifying anti-rheumatoid drugs (DMARDs) or glu-
cocorticosteroids. Evidence of infectious arthritis or crystal arthritis were considered exclusion
criteria [17]. Follow-up was 5 years, from January 2001 to December 2006.
Data collection included all variables needed to calculate DAS28-ESR, DAS28-CRP, SDAI,
CDAI and HUPI at baseline and at each 6-monthly visits [17]. For the present study only
patients fulfilling the 1987 ACR RA criteria along the follow-up were included. Most of these
patients started treatment with DMARDs at the beginning of follow-up (S2 Table). Therefore,
for the responsiveness analysis, baseline and 6 months visits were analyzed.
The EMECAR cohort. EMECAR was a prospective longitudinal cohort of prevalent RA
patients fulfilling 1987 ACR criteria [14] selected by random sampling in 34 Rheumatology
Units from Spain. Follow-up took place from November 1999 to December 2004 with yearly
visits. EMECAR database includes the required variables to calculate DAS28-ESR and HUPI,
but not DAS28-CRP, SDAI or CDAI, since global disease assessment by physician (GDA-Phy)
was not collected and C-reactive protein (CRP) values provided limited reliability. A detailed
description of the EMECAR cohort has been published previously [18].
At baseline, no patient was under treatment with a TNF-antagonist or leflunomide. During
4 years of follow-up, 27% of patient started, at least, one of these treatments. As we have previ-
ously described, improvement along the follow-up in this long term RA population was lim-
ited [18]. However, since HUPI was developed in patients with early arthritis, we included
information about EMECAR in order to compare the performance of HUPI compared to
DAS28 in long standing disease.
Responsiveness of HUPI
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Ethical statement
This is a secondary analysis of anonymized data from patients included in ACT-RAY, EME-
CAR and PROAR studies. ACT-RAY clinical trial was approved by the Research Ethical Com-
mittee (REC) of all centers included in the study (see Acknoledgement section “Group
ACT-RAY”). EMECAR study was approved by the REC of Hospital Universitario La Princesa
and this approval was accepted by all centers included in the study (see Acknoledgement sec-
tion “Group EMECAR”). PROAR study was approved by the REC of Hospital Universitario
La Princesa and this approval was accepted by all centers included in the study (see Acknol-
edgement section “Group PROAR”).
ACT-RAY, PROAR and EMECAR studies were conducted according to the principles
expressed in the Helsinki Declaration of 1983. All patients signed the respective written con-
sent before study entry [15, 17, 18].
Statistical analysis
We used STATA 12.0 for Windows (StataCorp LP, College Station, TX). To describe the three
populations, means and standard deviation (SD), medians and interquartile range (IQR), as
well as absolute and relative frequencies were used, depending on the distribution of variables.
The external responsiveness of HUPI was evaluated as recommended by Husted et al in
three different populations[19]. We used Pearson correlation coefficient to describe how
changes from baseline (ΔHUPI) to different follow-up visits (ACT-RAY visits 12, 24 or 52
weeks; PROAR visit 6 months; EMECAR visit 4 years) correlated with corresponding changes
in the values of global disease activity assessed by patient (ΔGDA-Pat), ΔGDA-Phy, ΔDA-
S28-ESR, ΔDAS28-CRP. Spearman correlation was used with ΔSDAI and ΔCDAI, since the
values of these indices do not follow a normal distribution. Internal responsiveness was also
evaluated using standardized effect size (SES) calculated with MS Excell 2007 for Windows as
the mean difference between baseline and each previously mentioned time points divided by
the pooled standard deviation, as described by Hedges and Olkin [20, 21].
We evaluated how HUPI-based response criteria[13] behave in comparison to EULAR
response criteria[22] using data from ACT-RAY. First, we tabulated the response with each set
of response criteria and cross-tabulated them. To determine the accuracy of both response cri-
teria, we used the percentage of correctly classified patients from the best fitted models with
ΔGDA-Phy as external criterion. ΔGDA-Phy was used to avoid circularity, since neither HUPI
nor DAS28 include this variable in their computation. Linear regression models using general-
ized linear solutions (Stata’s glm command with the default option) were performed with
ΔGDA-Phy (from baseline to different time points) as dependent variable and HUPI-based
and EULAR response criteria as categorical variables. Beta coefficients with 95% confidence
intervals (95%CI) for “Moderate” and “Good response” by either definition were reported,
along with the Akaike information criteria (AIC) from each model (S6 and S7 Tables). The
later allow us to identify the best model; given two different regression models fitted on the
same data, the model with the smallest AIC value is considered the best [23].
Results
Assessment of disease activity with different indices in three different
populations
Table 1 shows a description of the three study populations. In all three, about 75% of patients
were women and mean age at baseline ranged from 53 to 61 years. As part of the inclusion cri-
teria, patients from the early arthritis cohort had the disease for less than a year in contrast
Responsiveness of HUPI
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with about 8 years in ACT-RAY and EMECAR. As expected, patients from the clinical trial
showed the highest baseline disease activity and disability, EMECAR patients showed mid val-
ues, and those from PROAR showed the lowest scores of disease activity and disability
(Table 1).
As a result of HUPI allowing calculation from CRP or ESR, whichever available at the study
visit—a strategy to minimize missing data—, the HUPI was calculated in more visits than the
other indices in the three populations: 99.8% of visits in ACT-RAY; 96.7% in PROAR; and
92.3% in EMECAR, with the only exception of CDAI in PROAR: 98.6% (S3 Table).
In patients from ACT-RAY, baseline HUPI values show a “ceiling effect” with more than
40% of patients at the highest score of the index (12 units; upper left panel in Fig 1). The
remaining indices did not show this effect, with less of 5% at the highest value of SDAI and no
patient at the highest score of DAS28-ESR, DAS28-CRP and CDAI (remaining panels in
Fig 1). All indices showed improvement of disease activity after starting treatment with tocili-
zumab (Fig 1).
Patients from PROAR and EMECAR showed lower disease activity at baseline, so no “ceil-
ing effect” was observed in HUPI (Fig 1 left panels of mid and lower row). Disease activity
improvement with all indices was observed in PROAR after starting DMARD treatment in
this early arthritis population (Fig 1 mid row). Limited improvement was observed in EME-
CAR (Fig 1 lower row).
Responsiveness of HUPI versus traditional indices
Despite its baseline “ceiling effect” in the ACT-RAY clinical trial, the change in HUPI score at
week 12 had a good correlation with ΔGDA-Pat and slightly lower with ΔGDA-Phy. Conse-
quently, the correlation was very good with ΔDAS28 either with ESR or CRP, and slightly
lower with ΔSDAI or ΔCDAI (Table 2 and Fig 2).
In ACT-RAY correlations tended to improve when comparing ΔHUPI from baseline and
weeks 24 and 52 and the corresponding changes of the other variables (Table 2). Interestingly,
Table 1. Baseline characteristics of the populations.
ACT-RAY (n = 556) PROAR (n = 160) EMECAR (n = 789)
Female gender, n (%) 446 (80.0) 113 (70.6) 568 (72.0)
Age, median [IQR] 54 [46–62.5] 54 [44–68] 64 [54–71]
Disease duration, median [IQR] (years) 8.3±8.2� 0.37 [0.21–0.63] 8.7 [4.1–12.6]
Smoker, n (%) 200 (36.0) 60 (37.5) 274 (35.4)
RF positive, n (%) N.A. 47 (34.6) 578 (74.6)
ACPA positive, n (%) N.A. 76 (47.8) N.A.
HAQ, median [IQR] 1.5 [1–1.875] 0.5 [0–1.125] 1.125 [0.5–1.875]
HUPI, mean ± SD 10.9 ± 1.3 5.3 ± 3.1 6.5 ± 3.0
DAS28, mean ± SD 6.34 ± 0.99 3.84 ± 1.45 4.25 ± 1.40
DAS28-CRP, mean ± SD 6.44 ± 1.03 3.59 ± 1.33 N.A.
SDAI, median [IQR] 44.3 [34.1–55.5] 13.9 [6.0–21.7] N.A.
CDAI, median [IQR] 38.0 [28.8–47.2] 11.9 [4.6–20.4] N.A.
Abbreviations: n, number; IQR, interquartile range; SD, standard deviation; DO, disease onset; N.A., not available; RF, rheumatoid factor; ACPA anti-citrullinated
protein antibodies; HAQ, health assessment questionnaire; HUPI, Hospital Universitario La Princesa Index; DAS28, disease activity score calculated with erythrocyte
sedimentation rate and 28 joint counts; DAS28-CRP, disease activity score calculated with C-reactive protein and 28 joint counts; SDAI, simplified disease activity
index; CDAI, clinical disease activity index.
�IQR of disease duration was not available for ACT-RAY patients.
https://doi.org/10.1371/journal.pone.0214717.t001
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Fig 2 shows that there were individual important disparities (red dots) between ΔHUPI and
ΔSDAI or ΔCDAI.
We hypothesized that this correlation would not be perfect since HUPI was specifically
developed to avoid gender bias of DAS28 and SDAI. In addition, HUPI does not include
Fig 1. Evolution of disease activity during follow-up of the ACT-RAY, PROAR and EMECAR patients assessed with different
indices. Data are presented as interquartile range (p75 upper edge, p25 lower edge, p50 midline in the box), p95 (line above the box)
and p5 (line below the box). Dots represent outliers.
https://doi.org/10.1371/journal.pone.0214717.g001




















































































GDA: global disease assessment; Pat: patient; Phy: physician; HUPI: Hospital Universitario La Princesa Index; DAS28_ESR or _CRP: disease activity score calculated
with 28 joint counts and erythrosedimentation rate or C reactive protein; SDAI: simplified disease activity index; CDAI: clinical disease activity index; Data are shown as
the correlation coefficient (95% confidence interval).
https://doi.org/10.1371/journal.pone.0214717.t002
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GDA-Phy in its calculations. So, in order to be able to compare the respective sensitivity to
change (Internal responsiveness), we calculated the SES for each variable at the three time
points studied. The SES for HUPI was always the highest in the three populations at all times
studied (Fig 3 and S4 Table). In addition, the 95% CI of HUPI’s SES did not overlap with those
from GDA-Pat, GDA-Phy, SDAI and CDAI at any time in ACT-RAY (Fig 3A and S4 Table).
Similar findings were observed in patients from PROAR, although lower SES were observed
since the baseline disease activity was lower than that of patients in ACT-RAY (Fig 1), with no
significant differences across indices (Fig 3B and S4 Table).
On the other hand, limited disease activity improvement had been described with DAS28
in EMECAR[18] and the data with HUPI were consistent with these previous findings (Fig 3C
and S4 Table).
Comparison of EULAR response criteria and HUPI-based response criteria
In ACT-RAY, it was possible to determine HUPI response in more patients than with EULAR
response criteria either at week 12 (528 vs. 518), week 24 (509 vs. 503) or week 52 (418 vs. 412).
The lower number of assessments with EULAR response was due to missing ESR, required to
calculate DAS28. In addition, the proportion of patients with no response was higher with
HUPI than with EULAR response criteria, although gradually being the proportions closer
Fig 2. External responsiveness of HUPI (ΔHUPI) compared with improvement measured with other variables commonly used to assess clinical
improvement in rheumatoid arthritis. Red dots represent values in which there was clear discordance between ΔHUPI and other measuments of
improvement. The correlation coefficients are shown at Table 2.
https://doi.org/10.1371/journal.pone.0214717.g002
Responsiveness of HUPI
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along the follow-up (Fig 4A and 4B and S1 Fig panel A). Similar findings were observed in
PROAR and EMECAR (S2 Fig).
Table 3 shows that response to treatment was equally classified by both criteria in > 65% of
patients at week 12 and it gradually increased to >80% of patients at week 52. Three patients
were classified as good responders with EULAR response criteria and non-responders with
HUPI at all three time-points, whereas 1 patient was classified as good responder with HUPI
but non-responder with EULAR only at week 12. The characteristics of these patients are
shown in S5 Table. In summary, 3 patients had high number of tender joints, but low number
Fig 3. Internal responsiveness of different indices and variables used to assess disease activity in different cohorts.
Data are shown as the standardized effect size (black circle) and its 95% confidence interval (black bar) at A) week 52
for ACT-RAY patients; B) week 24 for PROAR patients; and C) year 4 for EMECAR patients.
https://doi.org/10.1371/journal.pone.0214717.g003
Responsiveness of HUPI
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of swollen joints, at baseline that improved in terms of tender joints but neither in terms of
swollen counts, nor APR or GDA-Pat. By contrast, the patient with no response by EULAR
criteria but good response with HUPI was a female patient with extremely high number of ten-
der joints that did not improve with treatment, whereas the remaining parameters were low at
baseline and improved with treatment.
Fig 4. Comparison of EULAR and HUPI response criteria from baseline at different weeks of patients from ACT-RAY. A) Percentage of patients
getting none, moderate or good response at week 12. B) Percentage of patients getting none, moderate or good response at week 52 (See S1 Fig panel A
for information at week 24). C) Association of change in global disease assessment by physician (GDA-Phy) with the different categories of EULAR
response (See S1 Fig panel B for information at weeks 12 and 24). D) Association of change in GDA-Phy with the different categories of HUPI response
(See S1 Fig panel B for information at weeks 12 and 24). Data in panels C and D are shown as the predicted mean change in GDA-Phy with its 95%
confidence interval for each category obtained from the linear regression models showed in S6 Table with the command marginsplot of Stata.
https://doi.org/10.1371/journal.pone.0214717.g004
Responsiveness of HUPI
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Finally, to analyze which response set may be more accurate, we used as external criterion
the ΔGDA-Phy from baseline to 12, 24 and 52 weeks. As shown in Fig 3C and S1 Fig panel B,
in average an improvement of GDA-Phy�20 was associated with no response at all time points
for HUPI response criteria and at week 12 for EULAR-RC. In the following time-points
EULAR no response tended to be associated with lower ΔGDA-Phy. Regarding moderate and
good responses, by HUPI criteria the average improvement in ΔGDA-Phy tended to be more
lineal, whereas by EULAR criteria, higher improvement in ΔGDA-Phy were needed to reach
moderate response and then lower improvements were needed to reach good response with
respect moderate response (Fig 2C and 2D and S2 Fig panel B). This can be appreciated with
the beta coefficients of the linear correlation models, in which the Akaike information criteria
was always lower for the models run with HUPI than with EULAR response, suggesting that
the former were better fitted (S6 Table). Similar results were observed in the PROAR and
EMECAR cohorts (S3 Fig and S7 Table).
Discussion
HUPI was developed in an intent to provide a more accurate tool for assessing disease activity
in patients with early RA and undifferentiated arthritis [12]. Validation is an ongoing process
and new instruments like the HUPI need to be tested in different populations; therefore, we
aimed to further validate HUPI by evaluating its responsiveness and the recently proposed
HUPI-based response criteria [13]. This was particularly necessary in patients from clinical tri-
als, whose baseline disease activity, as part of the general inclusion criteria, is usually very high.
At present, there is no gold standard to assess disease activity in RA, nevertheless we used pooled
indices of multiple measures that have been previously developed based on the Core Data Set
proposed by Felson et al[24]. All in all, the data presented in this work showed that HUPI exhib-
its comparable responsiveness to that of DAS28 and better than SDAI and CDAI. In addition,
our data suggest that HUPI-based response criteria are slightly more stringent than EULAR’s.
Baseline data from ACT-RAY have allowed confirming that in a clinical trial setting HUPI
has a “ceiling effect”, likely due to its design. Remarkably, this ceiling effect was not detected in
the other two cohorts more representative of patients seen in routine care. Nevertheless, in our
opinion, patients with 5 or more swollen and tender joints and GDA-Pat higher than 50/100
and CRP levels higher 1 mg/dl show very high disease activity and need special therapeutic
approaches irrespective of the magnitude of these variables above these limits.
Despite this “ceiling effect”, HUPI showed the largest sensitivity to change in all three popu-
lations, with SES superior to those of SDAI, CDAI and GDA, either by physician and patient.
We recognize that SES is not the best statistic to report responsiveness, as it is only assessing
internal responsiveness; however, it allows comparison across indices with varying range of
values. In addition, similar results were reported using other methods when we described the
index [12]. The poorer responsiveness of SDAI and CDAI may be a consequence of their
design’s simplicity, leading to non-normally distributed variables with a highly spread range of
Table 3. Distribution of patients from ACT-RAY depending on clinical response assessed either by EULAR or HUPI criteria at different time-points.
Week 12 (n = 518) Week 24 (n = 503) Week 52 (n = 412)
EULAR HUPI HUPI HUPI
None Moderate Good None Moderate Good None Moderate Good
None 40 5 1 11 3 0 5 2 0
Moderate 70 164 42 34 99 36 19 54 23
Good 3 47 146 3 43 274 3 26 280
Same response 67.6% 76.3% 82.3%
https://doi.org/10.1371/journal.pone.0214717.t003
Responsiveness of HUPI
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values in moderate and high disease activity. This can also explain the disparities in response
measurements showed at Fig 2.
On the other hand, since the responsiveness of HUPI is quite similar to that of DAS28, the
response criteria based in both indices behave very similarly. Small differences have been
detected, being HUPI slightly more stringent, with larger percentages of patients considered
non-responders in ACT-RAY compared to percentages of EULAR response. These differences
decreased along follow-up, although they were still detected at week 52, being the fast effect of
tocilizumab on APR a possible explanation, since ESR is highly weighted in DAS28 [25].
Another possibility to explain this discrepancy is the tender joint count, that is also highly
weighted in DAS28 and in HUPI is weighted differently by gender [12]. In this regard, it has
been described that the presence of fibromyalgia can interfere with the assessment of disease
activity with DAS28, since it impacts in the subjective components of the index, such as tender
joint count[26].
Nevertheless, it is difficult to know whether being HUPI-based response more stringent
than EULAR response may be an advantage or a disadvantage. In ACT-RAY, all patients were
treated with tocilizumab plus placebo or methotrexate, showing no statistical differences
between groups, but a statistical difference from baseline in both groups [15]. On these
grounds, we considered patients from both groups experiencing a similar change; however, it
was not our aim to evaluate treatment effect with any index. For this reason, we cannot deter-
mine whether HUPI-based response is as stringent in a “real” placebo group as in an active
treatment group, nor whether it helps discriminating the effect of the drug.
Conclusion
In summary, despite its “ceiling effect”, HUPI shows good responsiveness in all the scenarios
tested. In addition, the response criteria based on this new index seems to be more stringent
than the EULAR response criteria, although we need to deepen in the study of this characteris-
tic to determine whether it could be more efficient to detect differences between placebo and
active treatment.
Supporting information
S1 Fig. Comparison of EULAR and HUPI response criteria from baseline at different
weeks of patients from ACT-RAY. A) Percentage of patients getting none, moderate or good
response at week 24. B) Correlation of change in global disease assessment by physician
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Gonçalves, CR. Hospital das Clinicas–FMUSP. Brazil
Hansen, MS. Gentofte Hospital. Denmark
Hanvivadhanakul, P. Thammasat University Hospital. Thailand
Høili, C. Sykehuset Ostfold Moss HF. Norway
Hou, A. Inland Rheumatology; Clinical Trials, Inc. United States
Hunter, J. Gartnavel General Hospital. United Kingdom
Ilic, T. Clinical Centre of Vojvodina. Serbia
Ionescu, R. Spitalul Sf Maria. Romania
Kaine, J. Sarasota Arthritis Center. United States
Kakurina, N. Clinical Hospital of Daugavpils. Latvia
Kamalova, R. Republican clinical hospital. Russian Federation
Kelly, T. Innovative Health Research. United States
Knyazeva, L. GMU Kursk Regional Clinical Hospital. Russian Federation
Krumina, L. L.Krumina GP practice. Latvia
Responsiveness of HUPI
PLOSONE | https://doi.org/10.1371/journal.pone.0214717 April 10, 2019 13 / 19
Kurthen, R. Praxis Dr. med. Reiner Kurthen. Germany
Lagrone, RP. St. Thomas Hospital. United States
Lapadula, G. Ospedale Policlinico Di.M.I.M.P. Italy
Lavrentjevs, V. P.Stradins Clinical University Hospital. Latvia
Lawson, JG. Piedmont Arthritis Clinic. United States
Lazic, Z. Clinical Center Kragujevac. Serbia
Lejnieks, A. Rakus Clinic Linezers. Latvia
Levy, Y. Meir Medical Center. Israel
Lexberg, Å. Drammen sykehus Vestre Viken HF. Norway
Mader, R. Haemek Hospital. Israel
Mariette, X. Ch De Bicêtre. France
Markovits, D. Rambam Medical Center. Israel
Martin Mola, E. Htal. La Paz. Spain
Maugars, Y. Hopital Hotel Dieu Et Hme. France
Maymo Guarch, J. Hospital del Mar. Spain
Mazurov, VI. Sbei Of Hpe "Northwestern State Medical University N.A. I.I.Mechnikov".
Russian Federation
Mikkelsen, K. Revmatismesykehuset. Norway
Morovic Vergles, J. Clinical Hospital Dubrava. Croatia
Nabizadeh, S. Martina Hansen Hospital. Norway
Nanagara, R. Khon Kaen University. Thailand
Nasonov, EL. Fsbi "Scientific Research Institute Of Rheumatology" Of Russian Academy Of
Medical Sciences. Russian Federation.
Navarro Sarabia, F. Hospital Universitario Virgen Macarena. Spain
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Gómez Centeno E, Hospital Clinic i Provincial. Barcelona. Spain
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Jiménez Palop M, Hospital Nuestra Señora de Sonsoles. Avila. Spain
Juan Mas A, Hospital Son Llatzer. Palma de Mallorca. Spain
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Ramos López P, Hospital Prı́ncipe de Asturias. Alcala de Henares. Spain
Rivera Redondo J, Instituto Provincial de Rehabilitación. Madrid. Spain
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Pérez, M. Hospital Gral Carlos Haya, Malaga. Spain
Pujol, M. Hospital Mutua de Terrassa. Spain
Quirós, J. Hospital Fundación Alcorcón. Spain
Ribas, B. Hospital San Juan de Dios, Palma de Mallorca. Spain
Riera, M. Hospital Creu Roja, Barcelona. Spain
Rivera, J. Instituto Prov de Rehabilitación, Madrid. Spain
Rodrı́guez, JM. Hospital Univ de Getafe. Spain
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lez-Alvaro I. Influencia del género en la respuesta al tratamiento en una cohorte de pacientes con artritis
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